3/25
05:24 pm
nuvl
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025
Low
Report
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025
3/14
08:02 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $100.00 price target on the stock.
Low
Report
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $100.00 price target on the stock.
3/3
08:10 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
2/28
06:58 am
nuvl
Nuvalent to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
Low
Report
Nuvalent to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
2/28
06:30 am
nuvl
Nuvalent to Participate in Upcoming March Investor Conferences
Low
Report
Nuvalent to Participate in Upcoming March Investor Conferences
2/27
06:39 am
nuvl
Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Low
Report
Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2/27
06:30 am
nuvl
Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results
Low
Report
Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results
1/17
07:56 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
Low
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
1/13
06:17 pm
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $115.00 price target on the stock.
Low
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $115.00 price target on the stock.
1/13
06:30 am
nuvl
Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones
Medium
Report
Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones
12/30
07:37 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $110.00 price target on the stock.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $110.00 price target on the stock.